309 related articles for article (PubMed ID: 28201726)
1. Discontinuation, Efficacy, and Safety of Cholinesterase Inhibitors for Alzheimer's Disease: a Meta-Analysis and Meta-Regression of 43 Randomized Clinical Trials Enrolling 16 106 Patients.
Blanco-Silvente L; Castells X; Saez M; Barceló MA; Garre-Olmo J; Vilalta-Franch J; Capellà D
Int J Neuropsychopharmacol; 2017 Jul; 20(7):519-528. PubMed ID: 28201726
[TBL] [Abstract][Full Text] [Related]
2. Predictors of discontinuation, efficacy, and safety of memantine treatment for Alzheimer's disease: meta-analysis and meta-regression of 18 randomized clinical trials involving 5004 patients.
Blanco-Silvente L; Capellà D; Garre-Olmo J; Vilalta-Franch J; Castells X
BMC Geriatr; 2018 Jul; 18(1):168. PubMed ID: 30041625
[TBL] [Abstract][Full Text] [Related]
3. Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
O'Regan J; Lanctôt KL; Mazereeuw G; Herrmann N
J Clin Psychiatry; 2015 Nov; 76(11):e1424-31. PubMed ID: 26646039
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
Kavirajan H; Schneider LS
Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
[TBL] [Abstract][Full Text] [Related]
5. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
[TBL] [Abstract][Full Text] [Related]
6. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Dou KX; Tan MS; Tan CC; Cao XP; Hou XH; Guo QH; Tan L; Mok V; Yu JT
Alzheimers Res Ther; 2018 Dec; 10(1):126. PubMed ID: 30591071
[TBL] [Abstract][Full Text] [Related]
7. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of memantine for the treatment of Alzheimer's disease.
Matsunaga S; Kishi T; Nomura I; Sakuma K; Okuya M; Ikuta T; Iwata N
Expert Opin Drug Saf; 2018 Oct; 17(10):1053-1061. PubMed ID: 30222469
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis.
Trinh NH; Hoblyn J; Mohanty S; Yaffe K
JAMA; 2003 Jan; 289(2):210-6. PubMed ID: 12517232
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
12. Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Atri A; Frölich L; Ballard C; Tariot PN; Molinuevo JL; Boneva N; Windfeld K; Raket LL; Cummings JL
JAMA; 2018 Jan; 319(2):130-142. PubMed ID: 29318278
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Tan CC; Yu JT; Wang HF; Tan MS; Meng XF; Wang C; Jiang T; Zhu XC; Tan L
J Alzheimers Dis; 2014; 41(2):615-31. PubMed ID: 24662102
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Lanctôt KL; Herrmann N; Yau KK; Khan LR; Liu BA; LouLou MM; Einarson TR
CMAJ; 2003 Sep; 169(6):557-64. PubMed ID: 12975222
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy with cholinesterase inhibitors and memantine for Alzheimer's disease: a systematic review and meta-analysis.
Matsunaga S; Kishi T; Iwata N
Int J Neuropsychopharmacol; 2014 Dec; 18(5):. PubMed ID: 25548104
[TBL] [Abstract][Full Text] [Related]
16. Long-term cholinesterase inhibitor treatment of Alzheimer's disease.
Johannsen P
CNS Drugs; 2004; 18(12):757-68. PubMed ID: 15377166
[TBL] [Abstract][Full Text] [Related]
17. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Bullock R; Touchon J; Bergman H; Gambina G; He Y; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2005 Aug; 21(8):1317-27. PubMed ID: 16083542
[TBL] [Abstract][Full Text] [Related]
18. Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials.
Whitehead A; Perdomo C; Pratt RD; Birks J; Wilcock GK; Evans JG
Int J Geriatr Psychiatry; 2004 Jul; 19(7):624-33. PubMed ID: 15254918
[TBL] [Abstract][Full Text] [Related]
19. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
20. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
